Genprex to Participate and Present at Upcoming May Industry and Investor ConferencesPRNewsWire • 05/08/23
Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares riseProactive Investors • 04/19/23
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual MeetingPRNewsWire • 04/19/23
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases - Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks SoAccesswire • 04/19/23
Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for GlioblastomaPRNewsWire • 04/18/23
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene TherapiesPRNewsWire • 03/23/23
Genprex announces $4M direct offering with single, healthcare-focused institutional investorProactive Investors • 02/27/23
Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional InvestorPRNewsWire • 02/27/23
Genprex unveils groundbreaking data from primate study on its novel gene therapy to treat Type 1 diabetes at ATTD 2023 in BerlinProactive Investors • 02/23/23
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023PRNewsWire • 02/23/23
Genprex has an exciting gene therapy platform, Dawson James notes as it assigns Buy rating in initial coverageProactive Investors • 02/02/23
Genprex signs exclusive license to additional diabetes technology with University of PittsburghProactive Investors • 01/05/23
Genprex says research collaborators to present preclinical data highlighting potential of its gene therapy for Type 1 diabetes at Berlin conferenceProactive Investors • 01/04/23
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for DiabetesPRNewsWire • 01/04/23
Genprex boosts its diabetes gene therapy program with the license of additional technology from the University of PittsburghProactive Investors • 12/15/22
Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of PittsburghPRNewsWire • 12/15/22
Genprex gets green light for continuation of dose escalation Phase 1 of Acclaim-1 Phase 1/2 clinical trial of REQORSAProactive Investors • 12/14/22
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung CancerPRNewsWire • 12/14/22